Lilly Program Safety Analysis Plan Implementation and Bayesian Dose Response
View Presentation *Wei Wang, Eli Lilly And Company Keywords: SPERT, Program Safety Analysis Plan, PSAP, Bayesian, Dose Response I will share our experience implementing the Safety Planning, Evaluation and Reporting Team (SPERT) recommendation to develop a program safety analysis plan (PSAP) as a tool to proactively plan for meta-analysis of the program safety data. We focused on improving existing processes rather than building a brand new process. Our PSAP is an analytical plan for meta-analysis that is developed in conjunction with a program-level data collection plan. By providing a guidance document for the PSAP, we improved the consistency and efficiency of safety data analysis and were able to efficiently communicate and implement some innovative analytical methods for meta-analysis of safety data. I will also present a Bayesian dose response method for safety meta-analysis that appropriately analyzes dose response, without requiring all trials included in the analysis to have the same doses studied.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC